ICP-332 for Eczema: Four-Week Results, a Safety-First Trial and an Inconsistent Percentage
DOCTOR’S NOTES · ECZEMA EVIDENCE
A promising eczema tablet headline can leave two practical questions unanswered: how much evidence exists beyond the first month, and how carefully were safety findings reported? The 2026 ICP-332 paper is useful because it requires both questions. It should be read as early clinical research, not as instructions to obtain or take an experimental medicine.
What the trial actually tested
Xu and colleagues’ January 2026 primary abstract describes 75 adults aged 18–75 at 19 Chinese centers, studied in 2023. Participants with moderate-to-severe atopic dermatitis received 80 mg, 120 mg or placebo once daily for four weeks. Safety was the primary outcome.
| Week-four skin outcome | 80 mg | 120 mg | Placebo |
|---|---|---|---|
| Mean EASI percentage change | −78.2% | −72.5% | −16.7% |
| EASI-75 response | 64% | 64% | 8% |
EASI-75 means at least a 75% score improvement, not completely clear skin. Mean changes and responder percentages answer different questions. The abstract’s safety set had 74 people; treatment-emergent adverse events occurred in 76%, 75% and 68%, respectively, with no serious events or deaths reported.
A number that should not be copied without comment
The abstract prints decreased fibrinogen in the 80-mg group as 6/25 alongside 44%. Those values conflict: 6 divided by 25 is 24%. We retain the discrepancy rather than choosing a percentage as though the source were consistent. This is an arithmetic check, not a corrected medical dataset. The report should be clarified before that specific percentage is used to estimate risk.
Why four weeks cannot settle long-term safety
A short study can detect common early changes while missing uncommon or delayed problems. Likewise, zero serious events in a small trial does not establish zero risk. The number exposed, length of exposure and completeness of follow-up all affect what a safety observation can tell us. For a person balancing work, training and family, the important question is whether a treatment has an established monitoring and follow-up plan for their situation.
Do not rank the two doses solely because the lower dose had a numerically larger mean improvement. The displayed comparisons were with placebo; they do not by themselves prove that the lower dose is superior to the higher dose. Nor does a result in this adult study supply a pediatric dose or a prediction for someone with milder disease.
Questions for a treatment appointment
Bring the paper’s date and exact medicine name, then ask which locally available options fit the diagnosis, severity and previous treatment response. Ask what outcome will be tracked: visible signs, itch, sleep or ability to complete daily activities. A clinician can explain how a short research signal differs from the evidence and safety requirements used to choose care.
The AAD guideline hub provides a separate reference for established eczema management. A study summary should support that conversation rather than replace it. If a new article gives a striking percentage, keep the comparator and follow-up period attached when sharing it.
For another perspective on interpreting early findings, read Chitosan Eczema Clothing: Why Improvement From Baseline Did Not Prove an Advantage Over Cotton.
Where moisture care fits
Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not tested in the research discussed here. These findings do not establish pediatric efficacy or infant suitability for #003; ask a child’s clinician about an appropriate moisturizer.
Continue with a related question
- How to Read an Eczema Study Without Getting Misled by Percentages
- Your Eczema Itch Score and Your Rash Score Can Tell Different Stories
- What Is SCORAD? Understanding an Eczema Severity Score
Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational content does not diagnose an individual or imply independent medical review. Cited researchers and institutions do not endorse #003. Image is an AI-created editorial product illustration, not a patient photograph or clinical result.